Free Trial
LON:SNG

Synairgen (SNG) Share Price, News & Analysis

Synairgen logo
GBX 1.74 +0.02 (+1.16%)
As of 05:46 AM Eastern

About Synairgen Stock (LON:SNG)

Key Stats

Today's Range
1.71
1.89
50-Day Range
1.80
4.92
52-Week Range
1.71
10
Volume
1.46 million shs
Average Volume
2.62 million shs
Market Capitalization
£3.50 million
P/E Ratio
N/A
Dividend Yield
1.53%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

Receive SNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter.

SNG Stock News Headlines

Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Synairgen Share Chat (SNG)
See More Headlines

SNG Stock Analysis - Frequently Asked Questions

Synairgen's stock was trading at GBX 2.70 at the beginning of 2025. Since then, SNG shares have decreased by 30.5% and is now trading at GBX 1.88.
View the best growth stocks for 2025 here
.

Synairgen plc (LON:SNG) released its earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share (EPS) for the quarter.

Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca (AZN), Alibaba Group (BABA), boohoo group (BOO), Barclays (BARC), VanEck Gold Miners ETF (GDX) and Legal & General Group (LGEN).

Company Calendar

Last Earnings
9/29/2020
Today
1/22/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

Net Income
£-42,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£79,000.00
Cash Flow
GBX 0.92 per share
Book Value
GBX 26 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.50 million
Optionable
Not Optionable
Beta
-2.23
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (LON:SNG) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners